FlashDx will unveil its latest molecular diagnostic assays - Respiratory Panel 2 and MRSA/SA Panel — at MEDICA 2025, taking place from November 17–20, 2025, in Düsseldorf, Germany. The company will also demonstrate its fully automated multiplex molecular diagnostic system powered by its proprietary sSPRT™ (semi-Solid Phase Real-Time PCR) technology.
The FlashDx sSPRT™ platform enables rapid, accurate, and multiplex pathogen detection within a fully integrated “sample-to-result” workflow, designed to meet the growing needs of infectious disease and reproductive health diagnostics.
At this year’s exhibition, FlashDx will debut:
- Respiratory Panel 2 — targeting additional respiratory pathogens to complement the existing Respiratory Panel 1.1, expanding diagnostic coverage and clinical flexibility.
- MRSA/SA Panel — for rapid and precise detection of Methicillin-resistant Staphylococcus aureus (MRSA) and Staphylococcus aureus (SA), addressing key challenges in antimicrobial resistance testing.
The launch of these two assays further extends FlashDx’s multiplex molecular testing portfolio, reinforcing its commitment to advancing near-patient molecular diagnostics through innovation and automation.
FlashDx warmly welcomes visitors to Hall 3, Booth H26 at MEDICA 2025, to learn more about its latest technology breakthroughs and explore new opportunities for global collaboration or use the Request Information button below.
